国内严格抗菌药管理办法将出台,严格抗生素管理

2011-11-17 MedSci原创 MedSci原创

  记者获悉《抗菌药物临床应用管理办法》(以下简称《办法》)已经完成了征求意见稿,进入最终修订阶段,并拟在近日出台。   上周末(11日),卫生部医政司副司长赵明钢在接受媒体采访时表示,被称为史上最严厉的《办法》数易其稿,截至目前,已完成了向全社会征求反馈意见的工作,并进入最终修订过程。赵明钢解释道,该版本之所以被视为历届最严厉的一个版本,是因为其明确提出了管理的指标,包括考核指标;抗生素

  记者获悉《抗菌药物临床应用管理办法》(以下简称《办法》)已经完成了征求意见稿,进入最终修订阶段,并拟在近日出台。

  上周末(11日),卫生部医政司副司长赵明钢在接受媒体采访时表示,被称为史上最严厉的《办法》数易其稿,截至目前,已完成了向全社会征求反馈意见的工作,并进入最终修订过程。赵明钢解释道,该版本之所以被视为历届最严厉的一个版本,是因为其明确提出了管理的指标,包括考核指标;抗生素的分线使用,包括卫生行政部门和医疗机构的责任和义务。《办法》还将对抗菌药物的使用率、使用量进行排名和公示,引入社会监督机制,督促和提高医疗机构抗菌药物的合理使用水平。
  中国抗生素滥用现象值得重视。据统计,目前中国人均抗生素消费量在138克左右,而美国仅为13克,中美之间差距超过10倍。中国住院患者的抗生素使用比例超70%,外科手术使用率接近90%。
  赵明钢表示,即将颁布的《办法》对医院购入的抗菌药物数量进行了严格限定,并进一步明确医疗机构的负责人是抗菌药物使用管理的第一责任人。
  有专家建议,对我国抗生素的上游企业在生产和销售环节加强管理,也能起到促进合理用药的效果。卫生部合理用药专家委员会委员肖永红向记者介绍,我国抗生素品种多、产量高,每年的产量都超过使用量;因此卫生系统在抗生素的监管方面只执行到使用环节是不够的,应对抗生素的研究、生产和销售、使用等各个环节都施行严格管理。
  另据赵明钢介绍,未来我国要建立抗菌药物合理使用的长效机制,这样将便于社会和公众的监督,便于卫生行政部门的监管,也便于医疗机构的自律。
  赵明钢还表示,从本月初开始的抗菌药物专项治理督导检查工作的初步调查来看,现在二级甲等医院在抗生素使用方面,确实取得了阶段性的成果。卫生部从11月7日开始在全国范围进行每年一度的医疗质量万里行和抗菌药物专项治理的督导检查工作。(记者宦璐 )

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670871, encodeId=b7b116e0871f5, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Tue Jun 12 04:16:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955863, encodeId=f1401955863ed, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Fri Sep 07 14:16:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330492, encodeId=f2051330492fe, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372979, encodeId=4b1813e297979, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1670871, encodeId=b7b116e0871f5, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Tue Jun 12 04:16:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955863, encodeId=f1401955863ed, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Fri Sep 07 14:16:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330492, encodeId=f2051330492fe, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372979, encodeId=4b1813e297979, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670871, encodeId=b7b116e0871f5, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Tue Jun 12 04:16:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955863, encodeId=f1401955863ed, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Fri Sep 07 14:16:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330492, encodeId=f2051330492fe, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372979, encodeId=4b1813e297979, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1670871, encodeId=b7b116e0871f5, content=<a href='/topic/show?id=a83d554391b' target=_blank style='color:#2F92EE;'>#抗生素管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55439, encryptionId=a83d554391b, topicName=抗生素管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c126759283, createdName=lixiao3335, createdTime=Tue Jun 12 04:16:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955863, encodeId=f1401955863ed, content=<a href='/topic/show?id=82e6e602651' target=_blank style='color:#2F92EE;'>#管理办法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76026, encryptionId=82e6e602651, topicName=管理办法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b1f500, createdName=zengjiayao, createdTime=Fri Sep 07 14:16:00 CST 2012, time=2012-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330492, encodeId=f2051330492fe, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372979, encodeId=4b1813e297979, content=<a href='/topic/show?id=eb2555e176c' target=_blank style='color:#2F92EE;'>#抗菌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55717, encryptionId=eb2555e176c, topicName=抗菌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat Nov 19 12:16:00 CST 2011, time=2011-11-19, status=1, ipAttribution=)]
    2011-11-19 lhlxtx